Expressive

rs10038916 - GRIA1

Magnitude 2.2 · 2 studies on file

Reported associations

  • Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. - Nature genetics (2022) · Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Hinds DA, Gelernter J, Levey DF, Polimanti R, Stein MB, Van Someren EJW, Smit AB, Posthuma D · PubMed 35835914

    Insomnia is a heritable, highly prevalent sleep disorder for which no sufficient treatment currently exists. Previous genome-wide association studies with up to 1.3 million subjects identified over 200 associated loci. This extreme polygenicity suggested that many more loci remain to be discovered. The current study almost doubled the sample size to 593,724 cases and 1,771,286 controls, thereby increasing statistical power, and identified 554 risk loci (including 364 novel loci). To capitalize on this large number of loci, we propose a novel strategy to prioritize genes using external biological resources and functional interactions between genes across risk loci. Of all 3,898 genes naively implicated from the risk loci, we prioritize 289 and find brain-tissue expression spec

  • Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction - Unknown journal (n.d.) · Unknown authors · PubMed 38839884

    ABSTRACT: Restless legs syndrome (RLS) affects up to 10% of older adults. Their healthcare is impeded by delayed diagnosis and insufficient treatment. To advance disease prediction and find new entry points for therapy, we performed meta-analyses of genome-wide association studies in 116,647 individuals with RLS (cases) and 1,546,466 controls of European ancestry. The pooled analysis increased the number of risk loci eightfold to 164, including three on chromosome X. Sex-specific meta-analyses revealed largely overlapping genetic predispositions of the sexes (rg = 0.96). Locus annotation prioritized druggable genes such as glutamate receptors 1 and 4, and Mendelian randomization indicated RLS as a causal risk factor for diabetes. Machine learning approaches combining genetic and nongen

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Diet

  • fresh fruit intake Moderate

    Mendelian randomization analysis identifies fresh fruit consumption as causally protective against RLS with effect estimate of 33% risk reduction per unit increase

    target 2-3 servings of fresh fruit daily; prioritize variety and whole fruits over juices

Discuss with your doctor

  • glutamate receptor-targeting anticonvulsants for RLS Moderate

    GRIA1 encodes AMPA-type glutamate receptor; rs10038916 genetic signal and drug prioritioning indicate glutamate modulators and anticonvulsants (perampanel, lamotrigine) may address RLS pathophysiology

    discuss with neurologist or sleep medicine specialist whether glutamate receptor antagonists or alpha-2-delta ligands are appropriate for RLS symptoms

Lifestyle

  • sleep environment and morning routine optimization Moderate

    Mendelian randomization shows ease of waking in morning is causally protective against RLS (effect -0.30); sleep environment directly impacts RLS symptom severity

    maintain consistent sleep-wake schedule, optimize bedroom darkness and temperature, establish predictable morning routine

  • stress and tension management Moderate

    GWAS correlation and Mendelian randomization show bidirectional causal relationship between psychological tension and RLS; reducing stress is modifiable protective factor

    implement mindfulness, relaxation techniques, or structured stress-reduction program; consider cognitive behavioral therapy if anxiety present

Screening

  • restless legs syndrome symptom assessment High

    rs10038916-A (GRIA1) shows genome-wide significant association with RLS (p=9.99e-16) in meta-analysis of 1.66M+ individuals; primarily affects sleep quality and daytime functioning

    assess annually or when new symptoms emerge: evening leg restlessness, uncomfortable sensations, relief with movement during sleep

  • depression and anxiety symptoms Moderate

    Strong bidirectional genetic correlation between RLS and depression/anxiety; shared genetic and mechanistic pathways increase risk of both conditions in RLS carriers

    baseline mood assessment using PHQ-9 or similar; annual screening if risk factors present; discuss changes in mood or anxiety with provider

  • type 2 diabetes risk and blood glucose Moderate

    Mendelian randomization identifies unidirectional causal effect of RLS on type 2 diabetes (effect 0.99, p=1.5e-68); RLS genetic predisposition increases metabolic disease risk independently

    baseline fasting glucose and HbA1c; repeat screening every 1-3 years or per provider guidelines; monitor for polyuria, polydipsia